DDInter542 DDInter1562
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis include postmenopausal deficiency of estrogen and age-related deterioration in bone homeostasis. Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent therapies is critical. Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets. The main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation. Although rare, there was an increased risk of venous thromboembolism during clinical trials of postmenopausal women receiving raloxifene. In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene therapy compared to placebo.[label] It is strongly advised that the risk-benefit ratio is considered before starting raloxifene therapy in women at risk of thromboembolic disease or strokes, such as the prior history of stroke, transient ischemic attack, atrial fibrillation, hypertension, or cigarette smoking.[label]
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) resembles {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) binds {v} (Gene) GPR35
GPR35 {u} (Gene) regulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) resembles {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) binds {v} (Gene) GPR35
GPR35 {u} (Gene) regulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) binds {v} (Gene) CRYZ
CRYZ {u} (Gene) interacts with {v} (Gene) IKBKE
IKBKE {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Raloxifene
Dicoumarol {u} (Compound) resembles {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Raloxifene
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Raloxifene (Compound)
Dicoumarol (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is upregulated by Raloxifene (Compound)
Dicoumarol (Compound) binds GPR35 (Gene) and GPR35 (Gene) regulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Raloxifene (Compound)
Dicoumarol (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Raloxifene (Compound)
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Raloxifene (Compound)
Dicoumarol (Compound) binds GPR35 (Gene) and GPR35 (Gene) regulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Raloxifene (Compound)
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Raloxifene (Compound)
Dicoumarol (Compound) binds CRYZ (Gene) and CRYZ (Gene) interacts with IKBKE (Gene) and IKBKE (Gene) is upregulated by Raloxifene (Compound)
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Raloxifene (Compound)
Dicoumarol (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Raloxifene (Compound)